Celldex Therapeutics: Will They Get It Right After A Decade Of Failures?
Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...
Tabasco sauce helps validate simpler method for immune cell analysis in inflamed tissue
Neutrophil granulocytes, a type of immune cell, are indispensable for the defense against pathogens. However, if they migrate into injured tissue, for example into the brain after a stroke, they can ...
Everyday Health6d
What Is Histamine Intolerance
Histamine intolerance is a proposed condition in which a person may have difficulty metabolizing histamine in food. Learn ...